Sialyl compounds are essential components of various biological fluids but relatively little is known about their occurrence in the extracellular fluid of patients with end-stage renal disease. As we have developed a macropreparative method for concentrating and desalting a wide range of fractions from diluted biological fluids we have been able to isolate and identify 5 sialooligosaccharides, 3 sialosugarphosphates, 2 monosialoglycopeptides and 1 disialoglycopeptide. The structures have been elucidated predominantly by one and two-dimensional NMR spectroscopy, enzymatic degradation and FAB mass spectrometry.
The accumulation of these compounds in uremic sera may be of particular interest as they may interact in the molecular biology of diseases typically associated with the uremic state, e.g., immune deficiency, neurological disorders, receptor binding abnormalities, complement system disturbances and cell membrane alterations.
CorfieldAP, SchauerR.Occurrence of sialic acids. In: SchauerR, ed. Sialic acids: chemistry, metabolism and function.Wien, New York: Springer Verlag, 1982; 5–39.
2.
SchneckL, VolkBW, SaiferA.The gangliosides. Am J Med1969; 46:245–63.
3.
BergströmJ, FürstP.Uraemic toxins. In: DrukkerW, ParsonsFM, MaherJF, eds. Replacement of renal function by dialysis.Boston, The Hague, Dordrecht, Lancaster: Martinus Nijhoff Publishers, 1983; 354–90.
4.
ZimmermannL, BergströmJ, JörnwallH.A method for separation of middle molecules by high performance liquid chromatography: application in studies of glucuronyl-o-hydroxyhippurate in normal and uremic subjects. Clin Nephrol1986; 25:94–100.
5.
SchootsAC, HomanHR, GladdinesMM, CramersCAMG, De SmetR, RingoirSMG. Screening of UV-absorbing solutes in uremic serum by reversed phase HPLC: change of blood levels in different therapies. Clin Chim Acta1985; 146:37–51.
6.
BrunnerH, MannH.What remains of the “middle molecule” hypothesis today?Contrib Nephrol1985; 44:14–39.
7.
ShawAB. Haemolysis in chronic renal failure. Brit Med J1967; 2:213–16.
8.
ErslevAJ. Anemia of chronic renal disease. Arch Intern Med1970; 126:774–80.
9.
EssersU, MüllerW, BrunnerE.Zur Wirkung von Erythropoetin bei Gesunden und bei Patienten mit chronischer Urämie. Klin Wochenschr1973; 51:1005–9.
10.
EschbachJW, AdamsonJW. Anemia of end-stage renal disease. Kidney Int1985; 28:1–5.
11.
ZehnderC, BlumbergA.Human recombinant erythropoietin treatment in transfusion dependent anemic patients on maintenance hemodialysis. Clin Nephrol1989; 31:55–9.
12.
RaskovaJ, RaskaK.Humoral inhibitors of the immune response in uremia. Lab Invest1981; 45:410–7.
13.
MillerTE. Uraemia - does it affect host resistance to infectous disease?Eur J Clin Microbiol1984; 3:383–6.
14.
KonradPI, HusbergBS. The immuno-suppressive effect of experimentally induced uremia. Nephron1984; 38:183–7.
15.
ModaiD, WeissgartenJ, ShakedU, SegalS, PikA, FuchsR.Levamisole circumvents inhibition of lymphocyte activation imposed by uremic serum. Nephron1985; 40:436–9.
16.
KurzP, KöhlerH, MeuerSt, HütterothT, Meyer zum BüschenfeldeK-H. Impaired cellular immune responses in chronic renal failure: evidence for a T cell defect. Kidney Int1986; 29:1209–14.
17.
BoltonCF. Peripheral neuropathies associated with chronic renal failure. Can J Neurol Sci1980; 7:89–96.
18.
TegnèrR, BrismarT.Experimental uremic neuropathy. Part 1: decreased nerve conduction velocity in rats. J Neurol Sci1984; 65:29–36.
19.
BuoncristianiU, MazzottaG, CarobiC, GallaiV, CozzariM, Di PaoloNN. Control of uremic neuropathy by equilibrium peritoneal dialysis. Int J Artif Organs1984; 7:97–100.
20.
ZucchelliP, SturaniA.ZuccalàA, SantoroA, Degli E-spostiE, ChiariniC.Dysfunction of the autonomic nervous system in patients with end-stage renal failure. Contrib Nephrol1985; 45:69–81.
21.
HeidbrederE, SchafferhansW, HeidlandA.Autonomic neuropathy in chronic renal insufficiency. Nephron1985; 41:50–6.
22.
TegnèrR, LindholmB.Uremic polyneuropathy: different effects of hemodialysis and continuous ambulatory peritoneal dialysis. Acta Med Scand1985; 218:409–16.
23.
BiasioliS, D'AndreaG, FerianiM, Uremic encephalopathy: an updating. Clin Nephrol1986; 25:57–63.
TisoňP, KubiszP, ČernácekP, DzúrikR.Influence of inhibitor of glucose utilization on the blood platelet function. Nephron1983; 33: 253–6.
26.
Di MinnoG, MartinezJ, McKeanM-L, De La RosaJ, BurkeJF, ScottM.Platelet dysfunction in uremia: multi-faceted defect partially corrected by dialysis. Am J Med1985; 79:552–9.
27.
BazilinskiN, ShaykhM, DuneaG, Inhibition of platelet function by uremic middle molecules. Nephron1985; 40:423–8.
28.
KorrelSAM, ClemetsonKJ, Van HalbeekH, KamerlingP, SixmaJJ, VliegenhartJFG. Structural studies on the O-linked carbohydrate chains of human platelet glycocalicin. Eur J Biochem1984; 140:571–6.
29.
AkizawaT, SekiguchiT, NakayamaF, KitaokaT, KoshikawaS.Complement activation during hemodialysis: effects of membrane materials and anticoagulants. In: NoséY, KjellstrandC, IvanovichP, eds. Progress in artificial organs-1985.Cleveland: ISAO Press, 1986; 1169–73.
30.
HakimRM, BreillattJ, LazarusJM, PortFK. Complement activation and hypersensitivity reactions to dialysis membranes. N Engl J Med1984; 311:878–82.
BoginE, EaronY, BlumM.Effect of parathyroid hormone and uremia on erythrocyte deformability. Clin Chim Acta1986; 161:293–9.
37.
LeviJ, MalachiT, DjaldettiM, BoginE.Biochemical changes associated with the osmotic fragility of young and mature erythrocytes caused by parathyroid hormone in relation to the uremic syndrome. Clin Biochem1987; 20:121–5.
38.
De GiorgioL, MaffucciG, ToscanoG, GironiA, VignoliSt, SeghieriG.Plasma fibronectin in normolipidaemic and hyperlipidaemic uraemic patients treated with haemodialysis. Clin Chim Acta1987; 168:281–6.
39.
LewisSL, Van EppsDE, ChenowethDE. Leukocyte C5a receptor modulation during hemodialysis. Kidney Int1987; 31:112–20.
40.
BrunnerH, MannH, EssersU, SchultheisR, ByrneT, HeintzR.Preparative isolation of middle molecular weight fractions from the hemofiltrate of patients with chronic uremia. Artif Organs1978; 2:375–7.
41.
WeiβhaarG, BaumannW, FriebolinH, Isolierung und NMR-spektroskopische Charakterisierung sialin-säurehaltiger Verbindungen aus dem Hämofiltrat chronisch urämischer Patienten. Biol Chem Hoppe Seyler1987; 368:647–58.
42.
WeiβhaarG.Sialinsäurehaltige Verbindungen im Hämofiltrat chronisch urämischer Patienten: Isolierung und Strukturaufklärung. Heidelberg, Federal Republic of Germany: University of Heidelberg1987; 89 pp Dissertation.
43.
WarrenL.The thiobarbituric assay of sialic acids. J Biol Chem1959; 234:1971–5.
44.
KuhnR, BrossmerR.Über O-Acetyl-lactaminsäure-lactose aus Kuh-Colostrum und ihre Spaltbarkeit durch Influenza Virus. Chem Berichte1956; 89:2013–25.
45.
HuttunenJK, MiettinenTA. Quantitative determination of urinary neuraminyl oligosaccharides by gas-liquid chromatography. Anal Biochem1969; 29:441–58.
46.
ParkkinenJ, FinneJ.Isolation and structural characterization of five major sialyloligosaccarides and a sialylglycopeptide from normal human urine. Eur J Biochem1983; 136:355–61.
47.
Le MoelG, StreckerG, TroupelS, Carbohydrate content of middle molecular weight substances (MMWS) in uremic patients: preliminary results. Artif Organs1980; 4 (suppl.):37–40.
48.
KuhnR, GauheA.Bestimmung der Bindungsstelle von Sialinsäureresten in Oligosacchariden mit Hilfe von Perjodat. Chem Berichte1965; 98:395–13.
49.
BermanE.Determination of the structure of three oligosaccharides from normal human urine by using 60-MHz, carbon-13 nuclear magnetic resonance spectroscopy. Carbohydr Res1983; 118:9–20.
50.
MauryP.Excretion of neuraminic acid-containing trisaccharides in the urine during pregnancy. Clin Chim Acta1976; 71:335–8.
51.
ParkkinenJ, FinneJ.Isolation and characterization of novel phosphate-containing sialyloligosaccharides from normal human urine. Eur J Biochem1984; 140:427–31.
52.
FinneJ, KrusiusT, RauvalaH.Occurrence of disialosyl groups in glycoproteins. Biochem Biophys Res Commun1977; 74:405–10.
53.
FinneJ, KrusiusT, RauvalaH, HemminkiK.The disialosyl group of glycoproteins: occurrence in different tissues and cellular membranes. Eur J Biochem1977; 77:319–23.
54.
HayesML, CastellinoJ.Carbohydrate of the human plasminogen variants. J Biol Chem1979; 254:8768–80.
55.
EndoY, YamashitaK, TachibanaY, TojoS, KobataA.Structures of the asparagine-linked sugar chains of human chorionic gonadotropin. J Biochem1979; 85:669–79.
56.
KesslerMJ, ReddyMS, ShahRH, BahlOP. Structures of N-glycosidic carbohydrate units of human chorionic gonadotropin. J Biol Chem1979; 254: 7901–8.
57.
KesslerMJ, MiseT, GhaiRD, BahlOP. Structure and location of the O-glycosidic carbohydrate units of human chorionic gonadotropin. J Biol Chem1979; 254:7909–14.
58.
MarchesiVT, FurthmayrH, TomitaM.The red cell membrane. Ann Rev Biochem1976; 45:667–98.
59.
TomitaM, MarchesiVT. Amino-acid sequence and oligosaccharide attachment sites of human erythrocyte glycophorin. Proc Natl Acad Sci USA1975; 72:2964–8.
60.
ProhaskaR, KoernerTAWJr, ArmitageIM, FurthmayrH.Chemical and carbon-13 nuclear magnetic resonance studies of the blood group M and N active sialoglyco-peptides from human glycophorin A. J Biol Chem1981; 256:5781–91.
61.
LemmonnierM, BourillonR.Structural and immunological studies on a sialoglycopeptide isolated from human urine. Biochem Biophys Res Commun1975; 64:226–31.
62.
PooleAR. Proteoglycans in health and disease: structures and functions. Biochem J1986; 236:1–14.
